- Video: Morningstar Anti-Recession Funds
- Global Tobacco Stocks Sizzle
- Defense & Energy Stocks in Vogue
- Analysts Upbeat on Back-To-School Stocks
- Options Take Action on Banks and Amylin
- Economist Likes Chip & Multimedia Stocks
- Water Stocks Help You Stay Afloat
- Prescriptions for Your Portfolio
- Oil Services Stocks: 'Huge' Growth Ahead
- Three European Banks to Look At
- Video: Morningstar Anti-Recession Funds
- Microsoft's $300 Million Makeover
- Barbie v. Bratz: Debating the Payout
- CSX 'Welcoming' Work With Activist Hedge Funds: CEO
- Heinz CEO: Ketchup 'Better Than Vodka' in Russia
- Video: Morningstar Anti-Recession Funds
- Segway Polo Nerds; Also: Your Mortgage Hardball E-Mails
- Hot Sauce, Tepid Stock?
- Cramer: Lehman's a 'Lurking Black Hole'
- Fast Money Now – Bove Upgrades Lehman, Other Mid-Day Trades for Thursday
- Bernanke, In Key Speech, To Tackle Financial Stability
- Gap Profit Rises, Boosted by Improved Margins
- Best Trades Now: Energy, Defense, Food & More
- Why Markets Want Fannie, Freddie to Be Resolved
- Prescriptions for Fannie and Freddie
- Two Economic Indicators Show Continued Weakness
- Bonds Traders Prefer Fannie and Freddie Over Treasurys
- Jobless Claims Dip, But Overall Level Remains High
- Burger King Profit Up, Shares Fall on Margins
Health care stocks can earn investors big bucks, so long as they know which ones to pick, said William Muggia, portfolio manager at Touchstone Mid Cap Growth Fund.
"Health care is a very diverse group, so there's big winners and big losers," he said.
His fund's two largest holdings are Celgene [CELG
Loading...
()
] and Elan [ELN
Loading...
()
], whose multiple sclerosis drug Tysabri is "annualizing at $800 million" after being relaunched only two years ago.
But the company's biggest potential lies in its Alzheimer's treatments, Muggia said. Elan recently presented phase-two data on the disease, which will "potentially be the first disease-modifying agent ever in Alzheimer's," he said. The company will present the full data set on the drug July 29.
Muggia placed Elan's market cap at $16 billion.
Disclosure
Disclosure information was not immediately available for Muggia or his fund.
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes